Segment disclosures

Company overview

NAUTILUS BIOTECHNOLOGY, INC.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

1 dimension combinations 8 retained observations 4 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Reportable Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=naut:ReportableSegmentMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-30234000 USD20261027Open filing evidence
2026-01-01 – 2026-09-30424000 USD20261027Open filing evidence
2026-04-01 – 2026-06-30190000 USD20260728Open filing evidence
2026-01-01 – 2026-06-30190000 USD20260728Open filing evidence
2025-07-01 – 2025-09-300 USD20261027Open filing evidence
2025-01-01 – 2025-09-300 USD20261027Open filing evidence
2025-04-01 – 2025-06-300 USD20260728Open filing evidence
2025-01-01 – 2025-06-300 USD20260728Open filing evidence